Agomelatine: An antidepressant without deterioration of sexual response

Journal of Sex and Marital Therapy

Volumn 38, Issue 2, 2012, Pages 190-197

  Sapetti, Adrian ^a  

^a Centro Medico Sexologico   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; AGOMELATINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; LIBIDO; MALE; ORGASM; PATIENT SATISFACTION; PSYCHOSEXUAL DISORDER; TREATMENT OUTCOME;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIBIDO; MALE; ORGASM; PATIENT SATISFACTION; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858177092     PISSN: 0092623X     EISSN: 15210715     Source Type: Journal    
DOI: 10.1080/0092623X.2011.613095     Document Type: Article

References (13)

1. European Medicines Agency. 2010. CMHP assessment report for Valdoxan. Retrieved from http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-en6. pdf
2. Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., and Agomelatine Study Group. 2009. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 70: 1128-1137.
3. Hale, A., Corral, R., Mencacci, C., Saiz Ruiz, J., Albarran Severo, C., and, Gentil, V. 2010. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized, double-blind study. International Clinical Psychopharmacology, 25: 305-314.
4. Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W. J., Montejo, A. L., Smeraldi, E., and, Baylé, F. J. 2010. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. Journal of Clinical Psychiatry, 71: 109-120.
5. Kennedy, S. H., and, Emsley, R. A. 2006. Placebo controlled trial of agomelatine in the treatment of major depressive disorder. European Neuropsychopharmacology, 16: 93-100. (Pubitemid 43145814)
6. Kennedy, S. H., and, Rizvi, S. J. 2010. Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness. CNS Drugs, 24: 479-499.
7. Kennedy, S. H., Rizvi, S. J., Fulton, K., and, Rasmussen, J. 2008. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology, 28: 329-333.
8. Lo, H., Hale, A., and, DHaenen, H. 2002. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: A placebo controlled dose range study. International Clinical Psychopharmacology, 17: 239-247.
9. Moll, J. L., and, Brown, C. S. 2011. The use of monoamine pharmacological agents in the treatment of sexual dysfunction: Evidence in the literature. Journal of Sexual Medicine, 8: 956-970. doi:10.1111/j.1743-6109.2010.02190.x
10. Montejo, A. L., Llorca, G., Izquierdo, J. A., and, Rico-Villademoros, F. 2001. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry, 62: 10-21. (Pubitemid 32164676)
11. Montejo, A. L., Prieto, N., Terleira, A., Matias, J., Alonso, S., Paniagua, G., and, Portolés, A. 2010. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of Psychopharmacology, 24 (1): 111-120.
12. Olié, J. P., and, Kasper, S. 2007. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. International Journal of Neuropsychopharmacology, 10: 661-673. (Pubitemid 47517525)
13. Zajecka, J., Schatzberg, A., Stahl, S., Shah, A., Caputo, A., and, Post, A. 2010. Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 30: 135-44.